The effect of oral administration of ursodeoxycholic acid and high-dose proton pump inhibitors on the histology of Barrett's esophagus

Diseases of the Esophagus

Volumn 21, Issue 4, 2008, Pages 346-354

  Bozikas, A ^a   Marsman, W A ^a   Rosmolen, W D ^a   van Baal, J W P M ^a   Kulik, W ^a   ten Kate, F J W ^a   Krishnadath, K K ^a   Bergman, J J G H M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Barrett's esophagus; Dysplasia; Proliferation; Proton pump inhibition; Ursodeoxycholic acid

Indexed keywords

BILE ACID; CYCLOOXYGENASE 2; CYTOKERATIN 20; CYTOKERATIN 7; ESOMEPRAZOLE; KI 67 ANTIGEN; LANSOPRAZOLE; LOPERAMIDE; OMEPRAZOLE; PROTEIN P16; PROTEIN P53; PROTON PUMP INHIBITOR; URSODEOXYCHOLIC ACID; VILLIN;

ADULT; AGE; AGED; ARTICLE; BARRETT ESOPHAGUS; BILE COMPOSITION; CAPSULE ENDOSCOPY; CARDIA; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; EPITHELIUM DYSPLASIA; ESOPHAGITIS; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; SQUAMOUS EPITHELIUM; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 43449118109     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2007.00782.x     Document Type: Article

References (43)

1. 1 Blot W J, Devesa S S, Kneller R W, Fraumeni J F Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991 ; 265: 1287–9.
2. 2 Drewitz D J, Sampliner R E, Garewal H S. The incidence of adenocarcinoma in Barrett’s esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997 ; 92: 212–15.
3. 3 Hameeteman W, Tytgat G N, Houthoff H J, Van Den Tweel J G. Barrett’s esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989 ; 96: 1249–56.
4. 4 Shaheen N J, Crosby M A, Bozymski E M, Sandler R S. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology 2000 ; 119: 333–8.
5. 5 Albertsson M. Chemoradiotherapy of esophageal cancer. Acta Oncol 2002 ; 41: 118–23.
6. 6 Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999 ; 340: 825–31.
7. 7 Campos G M, Demeester S R, Peters J H et al. Predictive factors of Barrett esophagus: multivariate analysis of 502 patients with gastroesophageal reflux disease. Arch Surg 2001 ; 136: 1267–73.
8. 8 Ireland A P, Peters J H, Smyrk T C et al. Gastric juice protects against the development of esophageal adenocarcinoma in the rat. Ann Surg 1996 ; 224: 358–70.
9. 9 Triadafilopoulos G. Acid and bile reflux in Barrett’s esophagus: a tale of two evils. Gastroenterology 2001 ; 121: 1502–6.
10. 10 Vaezi M F, Richter J E. Importance of duodeno‐gastro‐esophageal reflux in the medical outpatient practice. Hepatogastroenterology 1999 ; 46: 40–7.
11. 11 Zaninotto G, Portale G, Parenti A et al. Role of acid and bile reflux in development of specialised intestinal metaplasia in distal oesophagus. Dig Liver Dis 2002 ; 34: 251–7.
12. 12 Talley N J, Abeygunasekera S. Bile reflux and Barrett’s oesophagus: innocent bystander or sinister companion? Dig Liver Dis 2002 ; 34: 246–8.
13. 13 Champion G, Richter J E, Vaezi M F, Singh S, Alexander R. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett’s esophagus. Gastroenterology 1994 ; 107: 747–54.
14. 14 Liron R, Parrilla P, Martinez de Haro L F et al. Quantification of duodenogastric reflux in Barrett’s esophagus. Am J Gastroenterol 1997 ; 92: 32–6.
15. 15 Shekels L L, Beste J E, Ho S B. Tauroursodeoxycholic acid protects in vitro models of human colonic cancer cells from cytotoxic effects of hydrophobic bile acids. J Lab Clin Med 1996 ; 127: 57–66.
16. 16 Guldutuna S, Zimmer G, Imhof M, Bhatti S, You T, Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]. Gastroenterology 1993 ; 104: 1736–44.
17. 17 Araki Y, Andoh A, Bamba H et al. The cytotoxicity of hydrophobic bile acids is ameliorated by more hydrophilic bile acids in intestinal cell lines IEC‐6 and Caco‐2. Oncol Rep 2003 ; 10: 1931–6.
18. 18 Invernizzi P, Salzman A L, Szabo C, Ueta I, O’Connor M, Setchell K D. Ursodeoxycholate inhibits induction of NOS in human intestinal epithelial cells and in vivo. Am J Physiol 1997 ; 273: G131–8.
19. 19 Peters F, Kara M, Rosmolen W et al. Poor results of 5‐aminolevulinic acid‐photodynamic therapy for residual high‐grade dysplasia and early cancer in barrett esophagus after endoscopic resection. Endoscopy 2005 ; 37: 418–24.
20. 20 Kara M A, Smits M E, Rosmolen W D et al. A randomized crossover study comparing light‐induced fluorescence endoscopy with standard videoendoscopy for the detection of early neoplasia in Barrett’s esophagus. Gastrointest Endosc 2005 ; 61: 671–8.
21. 21 Bergman J J. Gastroesophageal reflux disease and Barrett’s esophagus. Endoscopy 2005 ; 37: 8–18.
22. 22 Bootsma A H, Overmars H, Van Rooij A et al. Rapid analysis of conjugated bile acids in plasma using electrospray tandem mass spectrometry: application for selective screening of peroxisomal disorders. J Inherit Metab Dis 1999 ; 22: 307–10.
23. 23 Velanovich V, Karmy‐Jones R. Measuring gastroesophageal reflux disease: relationship between the Health‐Related Quality of Life score and physiologic parameters. Am Surg 1998 ; 64: 649–53.
24. 24 Velanovich V. Using quality‐of‐life measurements to predict patient satisfaction outcomes for antireflux surgery. Arch Surg 2004 ; 139: 621–5.
25. 27 Van Rees B P, Saukkonen K, Ristimaki A et al. Cyclooxygenase‐2 expression during carcinogenesis in the human stomach. J Pathol 2002 ; 196: 171–9.
26. 25 Yasuda H, Yamada M, Endo Y, Inoue K, Yoshiba M. Elevated cyclooxygenase‐2 expression in patients with early gastric cancer in the gastric pylorus. J Gastroenterol 2005 ; 40: 690–7.
27. 26 Kurtkaya‐Yapicier O, Gencosmanoglu R, Avsar E, Bakirci N, Tozun N, Sav A. The utility of cytokeratins 7 and 20 (CK7/20) immunohistochemistry in the distinction of short‐segment Barrett esophagus from gastric intestinal metaplasia: is it reliable? BMC Clin Pathol 2003 ; 3: 5.
28. 28 Baas I O, Mulder J W, Offerhaus G J, Vogelstein B, Hamilton S R. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994 ; 172: 5–12.
29. 29 Attri J, Srinivasan R, Majumdar S, Radotra B D, Wig J. Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma. BMC Gastroenterol 2005 ; 5: 22.
30. 30 Kauer W K, Peters J H, Demeester T R, Ireland A P, Bremner C G, Hagen J A. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re‐emphasized. Ann Surg 1995 ; 222: 525–31.
31. 31 Attwood S E, Smyrk T C, Demeester T R, Mirvish S S, Stein H J, Hinder R A. Duodenoesophageal reflux and the development of esophageal adenocarcinoma in rats. Surgery 1992 ; 111: 503–10.
32. 32 Miwa K, Sahara H, Segawa M et al. Reflux of duodenal or gastro‐duodenal contents induces esophageal carcinoma in rats. Int J Cancer 1996 ; 67: 269–74.
33. 33 Theisen J, Peters J H, Fein M et al. The mutagenic potential of duodenoesophageal reflux. Ann Surg 2005 ; 241: 63–8.
34. 34 Avidan B, Sonnenberg A, Schnell T G, Sontag S J. Gastric surgery is not a risk for Barrett’s esophagus or esophageal adenocarcinoma. Gastroenterology 2001 ; 121: 1281–5.
35. 35 Kaur B S, Ouatu‐Lascar R, Omary M B, Triadafilopoulos G. Bile salts induce or blunt cell proliferation in Barrett’s esophagus in an acid‐dependent fashion. Am J Physiol Gastrointest Liver Physiol 2000 ; 278: G1000–9.
36. 36 Crosignani A, Podda M, Battezzati P M et al. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 1991 ; 14: 1000–7.
37. 37 Rudolph G, Endele R, Senn M, Stiehl A. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis. Hepatology 1993 ; 17: 1028–32.
38. 38 Rost D, Rudolph G, Kloeters‐Plachky P, Stiehl A. Effect of high‐dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 2004 ; 40: 693–8.
39. 39 Ouatu‐Lascar R, Fitzgerald R C, Triadafilopoulos G. Differentiation and proliferation in Barrett’s esophagus and the effects of acid suppression. Gastroenterology 1999 ; 117: 327–35.
40. 40 Milkes D, Gerson L B, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol 2004 ; 99: 991–6.
41. 41 Yeh R W, Gerson L B, Triadafilopoulos G. Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett’s esophagus. Dis Esophagus 2003 ; 16: 193–8.
42. 42 Jolly A J, Wild C P, Hardie L J. Acid and bile salts induce DNA damage in human oesophageal cell lines. Mutagenesis 2004 ; 19: 319–24.
43. 43 Vaezi M F, Singh S, Richter J E. Role of acid and duodenogastric reflux in esophageal mucosal injury: a review of animal and human studies. Gastroenterology 1995 ; 108: 1897–907.